• 1
    Burns JC, Glodé MP. Kawasaki syndrome. Lancet 2004; 364: 53344.
  • 2
    Japanese Kawasaki Disease Research Committee. Diagnostic Guidelines of Kawasaki Disease, 5th edn. Tokyo: Japanese Kawasaki Disease Research Committee, 2002.
  • 3
    Abe J, Kotzin BL, Jujo K, Melish ME, Glode MP, Kohsaka T, Leung DYM. Selective expansion of T cells expressing T-cell receptor variable regions Vβ2 and Vβ8 in Kawasaki disease. Proc Natl Acad Sci USA 1992; 89: 406670.
  • 4
    Curtis N, Zheng R, Lamb JR, Levin M. Evidence for a superantigen mediated process in Kawasaki disease. Arch Dis Child 1995; 72: 30811.
  • 5
    Yoshioka T, Matsutani T, Iwagami S et al. Polyclonal expansion of TCRBV2- and TCRBV6-bearing T cells in patients with Kawasaki disease. Immunology 1999; 96: 46572.
  • 6
    Leung DYM, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki Syndrome. Lancet 1993; 342: 13858.
  • 7
    Pietra BA, De Inocencio J, Giannini EH, Hirsch R. TCR Vβ family repertoire and T cell activation markers in Kawasaki disease. J Immunol 1994; 153: 18818.
  • 8
    Leung DYM, Meissner HC, Shulman ST et al. Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. J Pediatr 2002; 140: 7426.
  • 9
    Horita N, Yokota S, Fuse S, Takamuro M, Tomita H, Sato K, Fuji N, Tsutsumi H. The throat flora and its mitogenic activity in patients with Kawasaki disease. Microbiol Immunol 2004; 48: 899903.
  • 10
    Terai M, Miwa K, Williams T, Kabat W, Fukuyama M, Okajima Y, Igarashi H, Shulman ST. The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J Infect Dis 1995; 172: 55861.
  • 11
    Morita A, Imada Y, Igarashi H, Yutsudo T. Serologic evidence that streptococcal superantigens are not involved in the pathogenesis of Kawasaki disease. Microbiol Immunol 1997; 41: 895900.
  • 12
    Nomura Y, Yoshinaga M, Masuda K, Takei S, Miyata K. Maternal antibody against toxic shock syndrome toxin-1 may protect infants younger than 6 months of age from developing Kawasaki syndrome. J Infect Dis 2002; 185: 167780.
  • 13
    Nomura Y, Masuda K, Yoshinaga M, Takei S, Miyata K. Possible relationship between streptococcal pyrogenic exotoxin A and Kawasaki syndrome in patients older than six months of age. Pediatr Infect Dis J 2003; 22: 7948.
  • 14
    Yoshioka T, Matsutani T, Toyosaki-Maeda T, Suzuki H, Uemura S, Suzuki R, Koike M, Hinuma Y. Relation of streptococcal pyrogenic exotoxin C as a causative superantigen for Kawasaki disease. Pediatr Res 2003; 53: 40310.
  • 15
    Miwa K, Fukuyama M, Sasaki R, Shimizu S, Ida N, Endo M, Igarashi H. Sensitive enzyme-linked immunosorbent assays for the detection of bacterial superantigens and antibodies against them in human plasma. Microbiol Immunol 2000; 44: 51923.
  • 16
    Sasse EA. Determination of reference intervals in the clinical laboratory using the proposed guideline national committee for clinical laboratory standards C28-P. Arch Pathol Laboratory Med 1992; 116: 7103.
  • 17
    Shlievert PM, Bohach GA, Ohlendorf DH et al. Molecular structure of Staphylococcus and Streptococcus superantigens. J Clin Immunol 1995; 15: 4S10S.
  • 18
    Proft T, Fraser JD. Bacterial superantigens. Clin Exp Immunol 2003; 133: 299306.
  • 19
    Kienle E, Buschmann HG. Specificity, cross-reactivity and competition profile of monoclonal antibodies to staphylococcal enterotoxin B and C1 detected by indirect enzyme-linked immunosorbent assays. Med Microbiol Immunol 1989; 178: 12733.
  • 20
    Hynes WL, Weeks CR, Iandolo JJ, Ferretti JJ. Immunologic cross-reactivity of type A streptococcal exotoxin (erythrogenic toxin) and staphylococcal enterotoxins B and C1. Infect Immun 1987; 55: 8378.
  • 21
    Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993; 91: 6027.
  • 22
    LeClaire RD, Bavari S. Human antibodies to bacterial superantigens and their ability to inhibit T-cell activation and lethality. Antimicrob Agents Chemother 2001; 45: 4603.
  • 23
    Durandy A, Fischer A, Griscelli C. Dysfunction of pokeweed mitogen-stimulated T and B lymphocytes response induced by gammaglobulin therapy. J Clin Invest 1981; 67: 86777.
  • 24
    Jason J, Gregg L, Han A, Hu A, Inge L, Eick A, Tham I, Campbell R. Immunoregulatory changes in Kawasaki disease. Clin Immunol Immunopthol 1997; 84: 296306.
  • 25
    Leung DYM, Siegel RL, Grady S, Krensky A, Meade R, Reinherz EL, Geha RS. Immunoregulatory abnormalities in mucocutaneous lymph node syndrome. Clin Immunol Immunopathol 1982; 23: 10012.
  • 26
    Williams O, Aroeira LS, Mengel J. T cell-dependent antibody response to staphylococcal enterotoxin B. Scand J Immunol 1995; 42: 30510.
  • 27
    Stohl W, Xu D, Zang S et al. In vivo staphylococcal superantigen-driven polyclonal Ig responses in mice: dependence upon CD4+ cells and human MHC class II. Int Immunol 2001; 13: 1291300.
  • 28
    Fuleihan R, Mourad W, Geha RS, Chatila T. Engagement of MHC-class II molecules by staphylococcal exotoxins delivers a comitogenic signal to human B cells. J Immunol 1991; 146: 16616.
  • 29
    Stohl W, Elliott JE, Linsley PS. Human T cell-dependent B cell differentiation induced by staphylococcal superantigens. J Immunol 1994; 153: 11727.